Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2013

View Archived Issues

Novel CETP inhibitors divulged by Boehringer Ingelheim

Eli Lilly patents novel GPR40 agonists for diabetes

Researchers at GlaxoSmithKline synthesize new RIP-2 inhibitors

Scientists at Bristol-Myers Squibb prepare novel agents for HIV infection

Merck & Co. and Alectos Therapeutics divulge novel O-GlcNAcase inhibitors

DRI unveils BioHub project for treatment of type 1 diabetes

miRagen Therapeutics licenses property from the University of Glasgow for PAH

VistaGen Therapeutics collaborates with Celsis to advance LiverSafe 3D

Phase III study of Sufentanil NanoTab PCA System meets primary endpoint

Targacept and AstraZeneca restructure collaboration

Presage Biosciences forms strategic research alliance with Celgene

TXA-127 shows promise in revascularization following ischemia

TopoTarget confirms final topline results from belinostat BELIEF trial

BORIS expression correlated with hepatocellular carcinoma prognosis

Inha mouse shows promise as a model for male reproductive development

GSK-744 LAP proves effective in monkeys with SHIV infection

MK-1439 shows good safety and efficacy in previously untreated HIV-infected patients

Stiefel receives positive recommendation by MHRA for new Duac combination

WuXi and Open Monoclonal Technology enter second agreement

Array BioPharma and Global Blood Therapeutics to form hematology collaboration

Clinical results reported for ATU-027 in patients with advanced solid tumors

Nymox provides update on U.S. phase II trial in early-stage prostate cancer

Roche gains FDA approval for next-generation test to evaluate response to hepatitis C therapy

FDA approves use of two Dako assays with Genentech's new breast cancer medicine

Avellino Lab USA launches first genetic test for Avellino corneal dystrophy